S-1/A: Endo Pharmaceuticals Revamps Director Compensation Policy Ahead of Potential Public Listing

Endo, Inc. amends and restates its non-employee director compensation policy, outlining annual equity and cash retainers effective July 23, 2024, as the company prepares for a possible public listing.

Summary

• Endo, Inc. has amended and restated its non-employee director compensation policy, effective July 23, 2024.
• The policy outlines annual compensation rates for eligible non-employee directors serving on the Board.
• The Board Chair will receive an annual equity retainer of $365,000 and an annual cash retainer of $135,000.
• Other non-employee directors will receive an annual equity retainer of $300,000 and an annual cash retainer of $75,000.
• Committee chairs (other than the Board Chair) will receive an additional annual cash retainer of $25,000 per committee.
• Other committee members (other than the Board Chair and committee chairs) will receive an additional annual cash retainer of $12,500 per committee.
• Annual equity retainers will generally be granted in the form of Restricted Stock Units (RSUs) under the company's 2024 Stock Incentive Plan.
• The Compensation & Human Capital Committee (CHC) has the discretion to grant all or a portion of the equity retainer in the form of a fixed cash amount.
• The number of RSUs granted will be calculated by dividing the equity retainer value by the fair market value of a share.
• For 2024, 2025, and 2026, equity retainers will be granted as a single RSU award (the Initial Grant) no later than 90 days following the effective date of the policy adoption.
• The Initial Grant will vest one-third on each of the first, second, and third anniversaries of the Grant Date, subject to continued service.
• Non-employee directors receiving an Initial Grant will not receive additional equity grants in 2025 or 2026.
• For directors appointed or elected outside the Annual Shareholders Meeting date, the CHC will determine the terms applicable to equity retainers, including potential proration.
• Subsequent annual equity retainers will be granted on the earlier of the first trading day after the Company's Annual Shareholders Meeting and the last trading day in June.
• These RSUs will vest in full upon the completion of one year of service following the Award Date, with continued vesting for directors not standing for re-election at the Annual Shareholders Meeting.
• All RSUs will fully vest upon a Change in Control of the Company.
• Annual cash retainers will be earned ratably over the annual service period and paid in arrears in quarterly installments.
• Cash retainers will be prorated for partial quarterly service.
• In the event a director's service ends, any earned but unpaid cash retainers will be paid as soon as administratively practicable.
• Unvested equity retainers, whether in the form of equity awards or cash, will be forfeited upon termination of service.
• The Company generally pays for or reimburses non-employee directors for transportation, hotel, food, and other incidental expenses related to attending Board and committee meetings or participating in Director education programs.

Sentiment

Score: 7

Explanation: The document is a standard corporate governance announcement, outlining compensation policies. The sentiment is neutral to positive, as it reflects a company taking steps to ensure effective leadership and governance.

Positives

• The policy provides a clear framework for compensating non-employee directors.
• The use of RSUs aligns directors' interests with those of shareholders.
• The vesting schedule encourages continued service.
• The policy is designed to be competitive to attract and retain qualified directors.
• The policy provides additional compensation for committee service, recognizing the additional workload and responsibilities.

Negatives

• Unvested equity retainers are forfeited upon termination of service, which may disincentivize directors from resigning even if it's in the best interest of the company.
• The CHC has broad discretion in determining the terms applicable to equity retainers granted to non-employee directors, which may lead to inconsistencies or perceived unfairness.

Risks

• The CHC's discretion in granting equity retainers in the form of cash may reduce the alignment of directors' interests with those of shareholders.
• The policy does not explicitly address the potential for clawback of compensation in cases of misconduct or financial restatements.

Future Outlook

The document does not provide a specific future outlook, but the policy is designed to attract and retain qualified directors, which is essential for the company's future success.

Industry Context

Director compensation is a standard practice in publicly-held companies to attract and retain qualified individuals to oversee the company's operations and strategy. The specific amounts and structure of compensation vary depending on the size, complexity, and industry of the company.

Comparison to Industry Standards

• Director compensation packages often include a mix of cash and equity, with the equity component designed to align directors' interests with those of shareholders.
• The specific amounts of compensation are typically benchmarked against peer companies in the same industry and of similar size.
• For example, comparable pharmaceutical companies such as Viatris, Organon, and Amneal Pharmaceuticals also utilize a mix of cash and equity in their director compensation packages.
• The use of RSUs is a common practice, as it provides directors with a direct stake in the company's long-term performance.
• The additional compensation for committee service is also a standard practice, recognizing the additional workload and responsibilities of committee members.

Stakeholder Impact

• Shareholders: The policy aims to attract and retain qualified directors, which can positively impact the company's performance and shareholder value.
• Directors: The policy outlines the compensation and benefits they will receive for their service.
• Employees: The policy may indirectly impact employees by ensuring effective leadership and governance.

Next Steps

• The CHC will determine the Grant Date for the Initial Grant of RSUs to eligible non-employee directors.
• The CHC will determine the terms applicable to equity retainers granted to non-employee directors appointed or elected outside the Annual Shareholders Meeting date.
• The company will make quarterly cash retainer payments to eligible non-employee directors.
• The company will continue to pay for or reimburse non-employee directors for transportation, hotel, food, and other incidental expenses related to attending Board and committee meetings or participating in Director education programs.

Key Dates

Keywords

director compensation, non-employee directors, equity retainers, cash retainers, restricted stock units, corporate governance, Endo, Inc., 2024 Stock Incentive Plan